Dr. Mark Ronald Pulera M.D.

Recommended Articles

• Comparisons Between Duchenne and Becker Muscular Dystrophy

  Muscular dystrophy is an inherited disease caused by abnormal levels of dystrophin in the body, a protein necessary for maintaining muscle integrity for movement and for heart functions. It is characterized by progressive muscle atrophy and is also linked to a heart condition called cardiomyopathy. ...

• Author Greg O'Brien Speaks About his Emotions Hijacked by Alzheimer's

  There are different types of memory related illnesses, something that many people know all too well unfortunately. Author and former newspaper editor Greg O’ Brien is one of them. He has spoken out about his experience with Alzheimer’s disease and how it has certainly impacted his life and those...

• What Is a Transient Ischemic Attack (TIA)?

  Transient ischemic attack (TIA) is type of the disease and it drops the blood supply to the brain temporarily. This is due to various reasons. It can make the brain deprive from the oxygen. The person gets stroke which is stroke like situations. Though it does not last long.The transient ischemic...

• On the Back of Friends: How One Man Travels the World with Muscular Dystrophy

  Everyone dreams of travelling the world at some point in life, and while this dream may envision backpacks, campfires, mobile speakers, inflatable mattresses and tons of supplies, very few people would dream of actually being backpacks on their thrilling adventure.Some four years ago, one of such...

• Cardiac Magnetic Resonance Imaging: Helping Muscular Dystrophy Patients with Oedema-Fibrosis

  Duchenne muscular dystrophy (DMD) is a genetic muscular disorder that targets the muscles and causes them to degenerate and weaken. Statistically, around 15,000 males are affected by the condition in the U.S. alone and approximately 300,000 around the world [1]. The most common and severe form of a...

• Nortis Inc. Receives $688K to Revolutionize Multiple Sclerosis Treatment

  One Seattle-based technology recently revealed new clinical technology that could completely change the way multiple sclerosis is treated. The firm received $668,000 to develop an in-vitro blood barrier that mimics the human blood-brain barrier, an innovation that would make MS drug development more...